Minorities Seek Presence On Cancer Review Panels

The mortality rate for prostate cancer is twice as high for African American men as it is for white men. The mortality rate for breast cancer is 1.35 times higher for African American women than for white women. Because of these discrepancies, reported by the National Center for Health Statistics, review panels that make cancer research funding decisions should include more African Americans, contend minority cancer advocates. "Without representation, there's not going to be funding," says W.

| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

The mortality rate for prostate cancer is twice as high for African American men as it is for white men. The mortality rate for breast cancer is 1.35 times higher for African American women than for white women. Because of these discrepancies, reported by the National Center for Health Statistics, review panels that make cancer research funding decisions should include more African Americans, contend minority cancer advocates.

"Without representation, there's not going to be funding," says W. Bedford Waters, chairman of the urology section of the National Medical Association, a Washington, D.C.-based professional organization for African American physicians. And without funding, science lacks the firepower to ask questions about the cause of the discrepancies, maintains Waters, a professor and associate director of urology at Loyola University Medical Center in Chicago. "Is it genetic? is it environmental? Is it dietary?" he asks.

Those unanswered questions prompted the American Cancer Society's (ACS's) ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Paul Smaglik

    This person does not yet have a bio.

Published In

Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo
Characterizing Immune Memory to COVID-19 Vaccination

Characterizing Immune Memory to COVID-19 Vaccination

10X Genomics
Optimize PCR assays with true linear temperature gradients

Applied Biosystems™ VeriFlex™ System: True Temperature Control for PCR Protocols

Thermo Fisher Logo

Products

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

iStock

Agilent BioTek Cytation C10 Confocal Imaging Reader

agilent technologies logo